Companies

SAB Biotherapeutics, Inc. (SABS) SEC filings

CIK 0001833214 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq, Nasdaq · incorporated in DE · fiscal year ends 12/31

Annual financials (from the company's own XBRL in its 10-K filings)

FY2025FY2024FY2023
Revenue (USD)02.2 M23.9 M
Net income (USD)13.3 M-42.2 M-18.7 M
Diluted EPS (USD/shares)-0.79-7.64-4.31

Latest filings

FiledFormDescriptionPeriod
2026-10-138-K8-K items 8.01,9.012026-10-13
2026-09-18442026-09-17
2026-08-21424B3424B3
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-12SCHEDULE 13GSCHEDULE 13G
2026-08-10SCHEDULE 13D/ASCHEDULE 13D/A
2026-08-0610-Q10-Q2026-06-30
2026-07-078-K8-K items 7.01,9.012026-07-07
2026-06-26442026-06-25
2026-06-188-K8-K items 5.072026-06-18
2026-05-15SCHEDULE 13G/ASCHEDULE 13G/A
2026-05-15SCHEDULE 13GSCHEDULE 13G
2026-05-15SCHEDULE 13GSCHEDULE 13G
2026-05-1210-Q10-Q2026-03-31
2026-05-048-K8-K items 1.01,9.012026-04-28
2026-05-01SCHEDULE 13GSCHEDULE 13G
2026-04-30DEF 14ADEF 14A2026-06-18
2026-04-228-K8-K items 7.01,9.012026-04-22
2026-03-31S-8S-8
2026-03-25442026-03-24

Forms on file (last 1,000): 4 112, 8-K 80, 3 34, 425 22, CORRESP 19, 10-Q 17, UPLOAD 14, EFFECT 12. Source: SEC EDGAR, as filed; this page is public data and not investment advice.

For software and AI agents: the same data as JSON, per call, no account: GET https://store.agentexchange.work/gw/filings/company?ticker=SABS (0.002 USD), /gw/filings/filings?ticker=SABS&form=8-K, /gw/filings/facts?ticker=SABS&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txt

Updated from EDGAR within 30 minutes of a filing. Agent Exchange